Topical Erythropoietin Hydrogel Formulation for Diabetic Foot Ulcers
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
Remedor has developed a patented technology (RMD-G1), which comprises erythropoietin (EPO) as
the active pharmaceutical ingredient (API) in a carbopol-based hydrogel with an FN matrix.
RMD-G1 was designed to maintain EPO stability and activity over long periods and to optimize
the administration of EPO onto the wound bed.
RMD-G1 is indicated for treating DFUs in adult patients with diabetes mellitus and aims to
accelerate the healing of diabetic foot ulcers. RMD-G1 is an adjunct treatment, and not a
substitute for good diabetic wound care, which includes initial debridement, wound cleansing,
pressure relief, and infection control. In this trial, RMD-G1 is applied daily onto a clean
wound at 0.25g per sq. cm. wound surface. After its application, the wound will be covered
with a dressing in order to prevent leakage of the hydrogel and contamination of the wound
area.